Outpatient Surgery Magazine

Special Edition: Anesthesia - July 2020 - Subscribe to Outpatient Surgery Magazine

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://magazine.outpatientsurgery.net/i/1268528

Contents of this Issue


Page 49 of 54

lam (3 mg), ketamine HCI (25 mg) and ondansetron (2 mg). The "melts" are placed under the patient's tongue before surgery and take effect within minutes. "Every facility has some form of oral sedation available for patients who refuse to have IVs started," says T. Hunter Newsom, MD, a cataract and refractive surgeon and the founder of the Newsom Eye & Laser Center in Sebring and Tampa, Fla. Not having to place an IV is only one of the reasons to use oral seda- tion for cataract patients. "Anesthesia approaches vary so widely, and sublingual sedation brings a greater consistency to the process because we can avoid first pass metabolism. It also has rapid onset," says Dr. Berdahl. The "sublingual troche" Dr. Berdahl uses generally is given in one-, one-and-a-half or two-tablet dosages. He estimates 40% of his cataract patients get one tablet, 30% get one and a half and the other 30% get two tablets before surgery. The dosage is driven primarily by age. "The older the patient, the less sedation they receive," says Dr. Berdahl. The final and, according to Dr. Berdahl, potentially greatest big-pic- ture benefit of oral sedation options is that they're opioid-free. "The ability to avoid fentanyl in cataract procedures is important," says Dr. Berdahl. "The literature shows patients who receive opioids only once can face problems of dependency." Obstacles to overcome With all the reported benefits, you'd think oral sedation would be a standard form of anesthesia for cataract surgeries. That's not the case. "There are some real barriers to adoption," says Dr. Berdahl. For one, the current form of the midazolam-ketamine-ondansetron tablet isn't an FDA-approved product. "Even though it's compounded at a 503(b) outsourcing facility that undergoes the same scrutiny as 5 0 • O U T P A T I E N T S U R G E R Y M A G A Z I N E • J U L Y 2 0 2 0

Articles in this issue

Archives of this issue

view archives of Outpatient Surgery Magazine - Special Edition: Anesthesia - July 2020 - Subscribe to Outpatient Surgery Magazine